LMG 324

Drug Profile

LMG 324

Alternative Names: LMG324

Latest Information Update: 07 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Alcon
  • Class Eye disorder therapies
  • Mechanism of Action Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Age-related macular degeneration

Most Recent Events

  • 23 Oct 2017 Alcon terminates a phase I/II trial in Age-related macular degeneration in USA based on management decision (Intravitreous) (NCT02398500)
  • 13 Jan 2017 Alcon suspends participant recruitment in a phase I/II trial in Age-related macular degeneration in USA (Intravitreous) (NCT02398500)
  • 01 Jul 2015 Phase-I/II clinical trials in Age-related macular degeneration in USA (Intravitreous)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top